Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02219724 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1 study of Neoplasms, sponsored by Genentech.

Completed
Registry status
Phase 1
Development phase
174
Enrollment target
20
Study locations

NCT02219724 is a Phase 1 study of Neoplasms that has completed, run by Genentech. The registered enrollment target is 174 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02219724, a Phase 1 study of Neoplasms, has completed, sponsored by Genentech.

COMPLETED
Registry status
Phase 1
Development phase
174 participants
Enrollment target
20
Study locations

Study Summary

This is a first-in-human, Phase 1, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of MOXR0916 administered intravenously in participants with locally advanced or metastatic solid tumors that have progressed after all available standard therapy or for which standard therapy has proven to be ineffective or intolerable, or is considered inappropriate. This study will consist of a screening period, an initial treatment period, a re-treatment period (for participants who discontinue MOXR0916 after demonstration of prolonged clinical benefit), and a post-treatment follow-up period. Participants will be enrolled in two stages: a dose-escalation stage and an expansion stage. The planned duration of the study is approximately 3 years.

Conditions Studied

Neoplasms

Interventions

  • DRUG MOXR0916

Study Locations (20)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston
  • Dana Farber Can Ins - Boston

Other

  • Institut Jules Bordet - Brussels
  • UZ Gent - Ghent
  • Sint Augustinus Wilrijk - Wilrijk

Victoria

  • Austin Hospital - Heidelberg
  • Peter Maccallum Cancer Centre - Melbourne

Arizona

  • HonorHealth Research Institute - Bisgrove - Scottsdale

Colorado

  • University of Colorado - Aurora

Connecticut

  • Yale School of Medicine - New Haven

District of Columbia

  • Georgetown University Medical Center Lombardi Cancer Center - Washington D.C.

Illinois

  • University Of Chicago Medical Center; Section Of Hematology/Oncology - Chicago

Trial Details

FieldValue
Enrollment Target 174 participants
Start Date 2014-08-12
Est. Completion 2019-08-18
Phase Phase 1

Sponsor

Genentech

332 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02219724

The ClinicalTrials.gov registry entry for NCT02219724 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (89% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which MOXR0916 is the first listed.

NCT02219724 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Massachusetts, Other, Victoria.

Frequently Asked Questions

What is clinical trial NCT02219724 about?

NCT02219724 is a clinical study titled "A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors". This is a first-in-human, Phase 1, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of MOXR0916 administered intravenously in participants with locally advanced or metastatic solid tumors that have progressed after all available stand...

What is the current status of trial NCT02219724?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2014-08-12. Estimated completion is 2019-08-18.

What conditions does trial NCT02219724 study?

This clinical trial studies the following conditions: Neoplasms.

What interventions are being tested in trial NCT02219724?

The interventions under investigation include: MOXR0916 (DRUG).

Who is sponsoring clinical trial NCT02219724?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02219724 being conducted?

This trial has 20 study locations across Arizona, Colorado, Connecticut, District of Columbia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.